Belgian clinical biotech developing microbiome-based Live Biotherapeutic Products for chronic inflammatory diseases.
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Series B MRM Health raised €55 million in a Series B led by pharmaceutical group Biocodex to complete Phase 2b of its microbiome drug for ulcerative colitis. | $63.8M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.